Yatai Pharmaceutical released its 2026 interim report. Total operating revenue was 158 million yuan, and net profit attributable to the parent company was negative 435,500 yuan, swinging from profit to loss. Compared with the same period last year, it decreased by 106 million yuan, a year-on-year decline of 100.41 percent. Net cash inflow from operating activities was negative 68.2129 million yuan, a year-on-year decline of 344.52 percent. The company's asset-liability ratio was 5.71 percent, gross margin was 34.27 percent, ROE was negative 0.04 percent, and diluted earnings per share was negative 0.00 yuan. The number of shareholders was 68,000, and the top ten shareholders held 20.37 percent of total share capital.
Zhejiang Yatai Pharmaceutical Co LtdCompany swung to a net loss in interim report, with revenue and cash flow declining sharply.
